Provided by Tiger Fintech (Singapore) Pte. Ltd.

INCANNEX HEALTHCARE LTD

0.2094
+0.00251.21%
Post-market: 0.20960.0002+0.10%16:59 EDT
Volume:9.26M
Turnover:1.93M
Market Cap:19.62M
PE:-0.17
High:0.2102
Open:0.2100
Low:0.2059
Close:0.2069
Loading ...

Incannex Healthcare Announces Strategic Warrant Cancellation to Reduce Potential Dilution and Enhance Shareholder Value

Reuters
·
20 May

Incannex Healthcare Inc. Expands Share Issuance Agreement to $2.5 Million Under Sales Agreement with A.G.P/Alliance Global Partners

Reuters
·
20 May

Incannex Healthcare Announces Potential 50% Reduction in Series A Warrants to Minimize Stockholder Dilution

Reuters
·
16 May

Incannex Healthcare Inc. Announces New Agreement with Warrant Holders, Reducing Series A Warrants in Exchange for Up to $12.5 Million in Net Proceeds

Reuters
·
16 May

Incannex Healthcare Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Incannex reports Q3 EPS (20c) vs. (38c) last year

TIPRANKS
·
15 May

Incannex Healthcare Q3 EPS $(0.20) Up From $(0.38) YoY

Benzinga
·
15 May

Incannex Healthcare Reports Q3 2025 Financials: Net Loss Narrows to $3.97M, Cash Reserves Surge to $6.71M

Reuters
·
15 May

Press Release: Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

Dow Jones
·
15 May

Dow Edges Higher; US Crude Oil Inventories Increase

Benzinga
·
15 May

Incannex Completes Phase 2 Dosing in Sleep Apnea Drug Trial; Shares Jump

MT Newswires Live
·
14 May

Incannex Healthcare Announces Completion of Patient Dosing in Phase 2/3 Study for Promising OSA Treatment IHL-42X, Topline Results Expected July 2025

Reuters
·
14 May

Incannex Healthcare Inc. Provides Clinical Program Update on Ihl-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (Osa)

THOMSON REUTERS
·
14 May

Incannex Healthcare Inc: Topline Results Expected in July 2025

THOMSON REUTERS
·
14 May

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
25 Apr

Incannex completes Phase 2 patient enrollment for RePOSA study of IHL-42X

TIPRANKS
·
03 Apr

BRIEF-Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa)

Reuters
·
03 Apr

Incannex Healthcare Completes Phase 2 Enrollment in Reposa Phase 2/3 Trial of Ihl-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (Osa)

THOMSON REUTERS
·
03 Apr

Incannex Healthcare Files Registration Statement for Sale of Shares

MT Newswires Live
·
25 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar